LEO Pharma AS
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$39.3M
Doctors Paid
253
Transactions
7,231
2024 Total
$214,704
Payment Breakdown by Category
Research$37.1M (94.4%)
Consulting$1.8M (4.6%)
Travel$315,210 (0.8%)
Food & Beverage$18,859 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $37.1M | 5,179 | 94.4% |
| Consulting Fee | $1.8M | 510 | 4.6% |
| Travel and Lodging | $315,210 | 902 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $80,262 | 35 | 0.2% |
| Food and Beverage | $18,859 | 605 | 0.0% |
Payments by Type
Research
$37.1M
5,179 transactions
General
$2.2M
2,052 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | $6.2M | 5 | 1,270 |
| TRALOKINUMAB MONOTHERAPY FOR MODERATE TO SEVERE ATOPIC DERMATITIS - ECZTRA 1 ECZEMA TRALOKINUMAB TRIAL NO. 1 ECZTRA 1 | $4.5M | 4 | 415 |
| TRALOKINUMAB MONOTHERAPY FOR MODERATE TO SEVERE ATOPIC DERMATITIS - ECZTRA 2 ECZEMA TRALOKINUMAB TRIAL NO. 2 ECZTRA 2 | $3.7M | 5 | 391 |
| LONG TERM STUDY LEO 90100 ON THE BODY | $2.6M | 3 | 235 |
| TRALOKINUMAB VACCINE RESPONSE TIME | $2.3M | 21 | 459 |
| DOSE-RANGING TRIAL TO EVALUATE DELGOCITINIB CREAM 1, 3, 8, AND 20 MG/G COMPARED TO DELGOCITINIB CREAM VEHICLE OVER AN 8-WEEK TREATMENT PERIOD IN ADULT SUBJECTS WITH ATOPIC DERMATITIS. | $2.0M | 1 | 158 |
| TRALOKINUMAB TRIAL IN ADJUNCT SETTING | $2.0M | 5 | 198 |
| TRALOKINUMAB CONFIRMATORY TRIAL IN ADOLESCENTS | $1.6M | 5 | 227 |
| TRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS | $1.1M | 3 | 215 |
| TRALOKINUMAB DRUG INTERACTION TRAIL | $731,555 | 1 | 92 |
| EXPLORATORY STUDY WITH LEO43204 IN ACNE VULGARIS | $603,296 | 0 | 16 |
| A TRIAL TO COMPARE THE INCIDENCE OF SCC AND OTHER SKIN NEOPLASIA ON SKIN AREAS TREATED WITH INGENOL DISOXATE GEL OR VEHICLE GEL FOR ACTINIC KERATOSIS ON FACE AND CHEST OR SCALP | $499,792 | 0 | 127 |
| PHASE 2B DOSE-RANGING TRIAL TO EVALUATE DELGOCITINIB CREAM 1, 3, 8, AND 20 MG/G COMPARED TO DELGOCITINIB CREAM VEHICLE OVER A 16-WEEK TREATMENT PERIOD IN ADULT SUBJECTS WITH CHRONIC HAND ECZEMA | $465,146 | 0 | 56 |
| EFFICACY AND SAFETY OF LEO 43204 IN FIELD TREATMENT OF ACTINIC KERATOSIS ON BALDING SCALP INCLUDING 12-MONTH FOLLOW-UP | $462,044 | 0 | 126 |
| EFFICACY AND SAFETY OF LEO 43204 IN FIELD TREATMENT OF ACTINIC KERATOSIS ON FACE OR CHEST INCLUDING 12-MONTH FOLLOW-UP | $416,060 | 2 | 83 |
| DELGOCITINIB CREAM FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS DURING 8 WEEKS IN ADULTS, ADOLESCENTS, AND CHILDREN | $408,781 | 8 | 220 |
| TRALOKINUMAB: DRUG INTERACTION TRAIL | $313,283 | 0 | 24 |
| TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB | $293,454 | 1 | 273 |
| PROTOPIC APPLES | $249,465 | 54 | 213 |
| PHASE 3, LEO 43204 COMPARED TO PLACEBO IN AK PATIENTS FACE | $231,744 | 0 | 50 |
| TRALOKINUMAB: VACCINE RESPONSE TIME | $145,117 | 0 | 55 |
| EFFICACY AND SAFETY OF INGENOL MEBUTATE GEL FOR ACTINIC KERATOSIS APPLIED ON LARGE AREA ON FACE, SCALP OR CHEST | $114,682 | 5 | 73 |
| EFFICACY AND SAFETY OF DELGOCITINIB CREAM IN DISCOID LUPUS ERYTHEMATOSUS. | $93,656 | 0 | 18 |
| BIOLOGICAL EFFECTS OF LEO 43204 IN ACTINIC KERATOSIS ASSESSED BY HISTOPATHOLOGY | $88,501 | 1 | 6 |
| TRALOKINUMAB: TRIAL IN ADJUNCT SETTING | $68,294 | 2 | 28 |
| AN OPEN-LABEL TRIAL TO EVALUATE THE FOOD EFFECT OF LEO 152020 FILM-COATED TABLETS | $48,016 | 0 | 1 |
| TRALOKINUMAB MONOTHERAPY FOR MODERATE TO SEVERE ATOPIC DERMATITIS - ECZTRA 1 (ECZEMA TRALOKINUMAB TRIAL NO. 1) (ECZTRA 1) | $39,966 | 1 | 12 |
| A TRIAL EVALUATING THE SAFETY AND EFFICACY OF ONCE DAILY TOPICAL TREATMENT WITH LEO 90100 AEROSOL FOAM IN ADOLESCENT SUBJECTS WITH PLAQUE PSORIASIS | $29,679 | 4 | 13 |
| TRALOKINUMAB MONOTHERAPY FOR MODERATE TO SEVERE ATOPIC DERMATITIS - ECZTRA 2 (ECZEMA TRALOKINUMAB TRIAL NO. 2) (ECZTRA 2) | $25,601 | 0 | 11 |
| DOSE-RANGING TRIAL TO EVALUATE DELGOCITINIB CREAM 1, 3, 8, AND 20 MGG COMPARED TO DELGOCITINIB CREAM VEHICLE OVER AN 8-WEEK TREATMENT PERIOD IN ADULT SUBJECTS WITH ATOPIC DERMATITIS. | $25,090 | 1 | 51 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Dermatology | $3.3M | 147 | $22,381 |
| Pediatric Dermatology | $305,621 | 7 | $43,660 |
| Pediatrics | $195,368 | 12 | $16,281 |
| MOHS-Micrographic Surgery | $107,493 | 15 | $7,166 |
| Clinical & Laboratory Dermatological Immunology | $59,865 | 2 | $29,933 |
| Pediatric Infectious Diseases | $48,735 | 1 | $48,735 |
| Internal Medicine | $24,563 | 7 | $3,509 |
| Hematology | $23,591 | 1 | $23,591 |
| Procedural Dermatology | $22,752 | 6 | $3,792 |
| Dermatopathology | $19,331 | 3 | $6,444 |
| Obesity Medicine | $19,122 | 1 | $19,122 |
| Allergy | $17,572 | 4 | $4,393 |
| Family Medicine | $17,563 | 4 | $4,391 |
| Endocrinology, Diabetes & Metabolism | $14,720 | 1 | $14,720 |
| Psychiatry | $13,240 | 1 | $13,240 |
| Specialist | $12,670 | 11 | $1,152 |
| Nephrology | $11,238 | 1 | $11,238 |
| Allergy & Immunology | $10,327 | 10 | $1,033 |
| Student in an Organized Health Care Education/Training Program | $4,597 | 3 | $1,532 |
| Pediatric Hematology-Oncology | $2,450 | 1 | $2,450 |
| Medical | $1,828 | 1 | $1,828 |
| Diagnostic Radiology | $1,610 | 1 | $1,610 |
| Pediatric Allergy/Immunology | $1,561 | 1 | $1,561 |
| Gynecology | $1,540 | 1 | $1,540 |
| Gastroenterology | $1,414 | 1 | $1,414 |
| Clinical & Laboratory Immunology | $1,200 | 1 | $1,200 |
| Family | $250.00 | 1 | $250.00 |
| Registered Nurse | $250.00 | 1 | $250.00 |
| General Practice | $75.80 | 2 | $37.90 |
| Otolaryngology | $37.90 | 1 | $37.90 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Matthew Zirwas, Md, MD | Dermatology | Bexley, OH | $1.0M | $0 |
| Lawrence Eichenfield, M.d, M.D | Pediatric Dermatology | San Diego, CA | $274,656 | $0 |
| Dr. Lawrence Parish, Md, MD | Dermatology | Philadelphia, PA | $260,138 | $0 |
| Dr. Jonathan Silverberg, Md, Phd, Mph, MD, PHD, MPH | Dermatology | Washington, DC | $238,910 | $0 |
| Emma Guttman, Md, MD | Dermatology | New York, NY | $204,610 | $0 |
| Dr. Michael Heffernan, Md, MD | Dermatology | San Luis Obispo, CA | $154,044 | $0 |
| Eric Simpson, Md, MD | Dermatology | Portland, OR | $145,393 | $0 |
| Mrs. Amy Paller, Md, MD | Pediatrics | Chicago, IL | $144,918 | $0 |
| Unknown Provider | — | — | $104,937 | $0 |
| Lisa Beck, M.d, M.D | Dermatology | Rochester, NY | $87,008 | $0 |
| Mr. Lawrence Osman, Md, MD | Dermatology | Northridge, CA | $79,133 | $0 |
| Linda Stein Gold, M.d, M.D | Dermatology | West Bloomfield, MI | $73,775 | $0 |
| Bruce Strober, M.d, M.D | Dermatology | Cromwell, CT | $60,816 | $0 |
| David Cohen, M.d, M.D | Dermatology | New York, NY | $59,313 | $0 |
| April Armstrong, Md, MD | Clinical & Laboratory Dermatological Immunology | Los Angeles, CA | $57,185 | $0 |
| Steven Feldman, Md, MD | Dermatology | Winston Salem, NC | $52,290 | $0 |
| Firas Hougeir, M.d, M.D | MOHS-Micrographic Surgery | Douglasville, GA | $50,913 | $0 |
| Michael Cohen-Wolkowiez, Md, MD | Pediatric Infectious Diseases | Durham, NC | $48,735 | $0 |
| Victoria Kuohung, Md, MD | Dermatology | Quincy, MA | $48,546 | $0 |
| Dr. Charles Ellis, Md, MD | Dermatology | Ann Arbor, MI | $43,414 | $0 |
| Kenneth Gordon, M.d, M.D | Dermatology | Wauwatosa, WI | $42,509 | $0 |
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $34,521 | $0 |
| Justin Ko, Md, MD | Dermatology | Stanford, CA | $34,125 | $0 |
| Dr. Brian Kim, Md, MD | Dermatology | Saint Louis, MO | $32,925 | $0 |
| Craig Elmets, Md, MD | Dermatology | Birmingham, AL | $32,858 | $0 |
About LEO Pharma AS
LEO Pharma AS has made $39.3M in payments to 253 healthcare providers, recorded across 7,231 transactions in the CMS Open Payments database. In 2024, the company paid $214,704. The top product by payment volume is ENSTILAR ($826,193).
Payments were distributed across 30 medical specialties. The top specialty by payment amount is Dermatology ($3.3M to 147 doctors).
Payment categories include: Food & Beverage ($18,859), Consulting ($1.8M), Research ($37.1M), Travel & Lodging ($315,210).
LEO Pharma AS is associated with 2 products in the CMS Open Payments database.